Study: NCT06053749

Intervention type: DRUG
Intervention: Avonex (IFNβ-1-a, Biogen Netherlands B.V)
Description: Information on drug use in hospitals and outpatient clinics are not recorded in the drug registers used in the study and, thus, information on exposure to these medications is not available.

Intervention type: DRUG
Intervention: Avonex (IFNβ-1-a, Biogen Netherlands B.V)
Description: Information on drug use in hospitals and outpatient clinics are not recorded in the drug registers used in the study and, thus, information on exposure to these medications is not available.

Intervention type: DRUG
Intervention: Rebif (IFNβ-1-a, Merck Europe B.V.)
Description: Information on drug use in hospitals and outpatient clinics are not recorded in the drug registers used in the study and, thus, information on exposure to these medications is not available.

Intervention type: DRUG
Intervention: Rebif (IFNβ-1-a, Merck Europe B.V.)
Description: Information on drug use in hospitals and outpatient clinics are not recorded in the drug registers used in the study and, thus, information on exposure to these medications is not available.

Intervention type: DRUG
Intervention: Extavia (IFNβ-1-b, Novartis Europharm Limited)
Description: Information on drug use in hospitals and outpatient clinics are not recorded in the drug registers used in the study and, thus, information on exposure to these medications is not available.

Intervention type: DRUG
Intervention: Extavia (IFNβ-1-b, Novartis Europharm Limited)
Description: Information on drug use in hospitals and outpatient clinics are not recorded in the drug registers used in the study and, thus, information on exposure to these medications is not available.

Intervention type: DRUG
Intervention: Betaseron (IFN-β-1-b, BAY86-5046, Bayer AG)
Description: Information on drug use in hospitals and outpatient clinics are not recorded in the drug registers used in the study and, thus, information on exposure to these medications is not available.

Intervention type: DRUG
Intervention: Betaseron (IFN-β-1-b, BAY86-5046, Bayer AG)
Description: Information on drug use in hospitals and outpatient clinics are not recorded in the drug registers used in the study and, thus, information on exposure to these medications is not available.

Intervention type: DRUG
Intervention: Plegridy (Peg IFNβ-1-a, Biogen Netherlands B.V)
Description: Information on drug use in hospitals and outpatient clinics are not recorded in the drug registers used in the study and, thus, information on exposure to these medications is not available.

Intervention type: DRUG
Intervention: Plegridy (Peg IFNβ-1-a, Biogen Netherlands B.V)
Description: Information on drug use in hospitals and outpatient clinics are not recorded in the drug registers used in the study and, thus, information on exposure to these medications is not available.

Intervention type: DRUG
Intervention: MS disease modifying drugs (MSDMDs)
Description: Information on drug use in hospitals and outpatient clinics are not recorded in the drug registers used in the study and, thus, information on exposure to these medications is not available.

Intervention type: DRUG
Intervention: MS disease modifying drugs (MSDMDs)
Description: Information on drug use in hospitals and outpatient clinics are not recorded in the drug registers used in the study and, thus, information on exposure to these medications is not available.